Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ipilimumab + nivolumab by Bristol-Myers Squibb for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Pre-Registration for Transitional Cell Carcinoma (Urothelial Cell...
Ipilimumab + nivolumab by Bristol-Myers Squibb for Malignant Fibrous Histiocytoma: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Malignant Fibrous Histiocytoma. According...
Ipilimumab + nivolumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Transitional (Urothelial) Tract...
Ipilimumab + nivolumab by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to...
Ipilimumab + nivolumab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Uveal Melanoma. According...
Ipilimumab + nivolumab by Bristol-Myers Squibb for Dedifferentiated Liposarcoma: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma. According to...
Ipilimumab + nivolumab by Bristol-Myers Squibb for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Gastroesophageal (GE) Junction Carcinomas....
Ipilimumab + nivolumab by Bristol-Myers Squibb for Metastatic Pancreatic Cancer: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Pancreatic Cancer. According...
Ipilimumab + nivolumab by Bristol-Myers Squibb for Ovarian Cancer: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer. According to...